Author:
Jardim Denis L Fontes,Conley Anthony,Subbiah Vivek
Abstract
Abstract
Background
Phyllodes tumors are uncommon breast tumors that account for less than 0.5% of all breast malignancies. After metastases develop, the prognosis is poor, with very few patients living more than 1 year. The biology of this unusual cancer is not understood and, consequently, no potential targets for treatments are currently available. There has been an exponential increase in the number of commercially available tumor profiling services. Herein, we report a case of metastatic malignant phyllodes tumor for which a comprehensive molecular analysis was performed by using Clinical Laboratory Improvement Amendments (CLIA)-certified labs, providing new insights into the potential opportunities for molecularly targeted therapies for this extremely rare disease.
Methods
Next-generation sequencing was performed by using the FoundationOne™ platform (Foundation Medicine, Cambridge, MA). Whole-genome array-based comparative genomic hybridization (array CGH) was performed by using the DNAarray™ (CombiMatrix Diagnostics, Irvine, CA). Immunohistochemical and morphoproteomics analysis were performed at Consultative proteomics®, The University of Texas, UT Health Medical School, Houston,TX (Robert E Brown Lab); Clarient Diagnostics, Aliso Viejo, CA; and Caris Life Sciences Target one, Irving, TX, USA.
Results
Next-generation sequencing showed 3 aberrant genes: activating mutation Q61L on NRAS; inactivating mutations Q504* and K740* on RB1; and TP53 loss. Whole-genome array-based comparative genomic hybridization (array CGH) revealed amplifications of chromosome (chr.) 1 (CKS1B gene), chr. 8 (MYC gene), and chr. 9 (CDKN2A gene) Deletions of chr. 17 (TP53), chr. 10 (GATA3), chr. 11 (FGF4 and CCND1 genes), and chr.22 (PDGFβ). Immunohistochemical analysis for relevant markers showed a positive staining for transducing-like enhancer of split (TLE) 3; secreted protein acidic and rich in cysteine (SPARC) was expressed at 2-3+ in the cytoplasm of the tumors cells, whereas mammalian target of rapamycin (mTOR) was expressed up to 2+ in the nuclei of the tumor cells.
Conclusions
We describe for the first time an NRAS mutation with concomitant activation of PI3K/Akt/mTOR in phyllodes tumor. We also found markers for sensitivity to taxane-based therapies, especially albumin-bound paclitaxel. Exploring the biology of rare malignancies by CLIA certified labs may be reasonable strategy for the development of targeted treatments.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Genetics(clinical),General Medicine
Reference31 articles.
1. Geisler DP, Boyle MJ, Malnar KF, McGee JM, Nolen MC, Fortner SM, Broughan TA: Phyllodes tumors of the breast: a review of 32 cases. Am Surg. 2000, 66 (4): 360-366.
2. Bellocq JP, Magro G: Fibroepithelial tumours. World Health Organization classification of tumours: Pathology and genetics tumours of the breast and female genital organs. Edited by: Tavassoli FAD,P. 2003, Lyon: IARC Press, 99-103.
3. Hawkins RE, Schofield JB, Fisher C, Wiltshaw E, McKinna JA: The clinical and histologic criteria that predict metastases from cystosarcoma phyllodes. Cancer. 1992, 69 (1): 141-147. 10.1002/1097-0142(19920101)69:1<141::AID-CNCR2820690125>3.0.CO;2-1.
4. Moffat CJ, Pinder SE, Dixon AR, Elston CW, Blamey RW, Ellis IO: Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. Histopathology. 1995, 27 (3): 205-218. 10.1111/j.1365-2559.1995.tb00212.x.
5. Mokbel K, Price RK, Mostafa A, Wells CA, Carpenter R: Phyllodes tumour of the breast: a retrospective analysis of 30 cases. Breast. 1999, 8 (5): 278-281. 10.1054/brst.1999.0058.
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献